Phaseline

Companies › Lyvgen Biopharma Holdings

Lyvgen Biopharma Holdings: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LVGN6051
4-1BB agonistic antibody
TNFRSF9Phase 2Head and Neck Squamous Cell CarcinomaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06378177LVGN6051Phase 2Head and Neck Squamous Cell CarcinomaOncologyOct 2027

Targets

TNFRSF9 (1)

Companies with the same targets

Pfizer Genmab Pieris Pharmaceuticals

Companies built like this

Pieris Pharmaceuticals iOnctura Toray Industries SynerGene Therapeutics Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.